Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 8
Basal insulin market penetration with TresibaⓇ supported
by XultophyⓇ launches
TresibaⓇ value market share of basal insulin
segment in selected countries outside the US
Combined value market share of TresibaⓇ and
XultophyⓇ in selected countries
Switzerland
Japan
Mexico
40%
Netherlands
Spain
Denmark
UK
Argentina
― Brazil
Greece
Italy
Switzerland
France (XultophyⓇ only)
Sweden
42%
60%
-32%
30%
32%
28%
40%
25%
23%
20%
19%
19%
-13%
13%
20%
10%
.14%
7%
0%
0
10
20
30
40
50
Months from launch
0%
10
Note: Limited IQVIA (formerly IMS) coverage in India
Source: IQVIA (formerly IMS), Monthly value figures, Nov 2017
changing
diabetes®
Greece ■■■TresibaⓇ share
30
20
Months from launch¹
Source: IQVIA (formerly IMS), Monthly value figures, Nov 2017
43%
40
50
1 Switzerland, Sweden and Greece: Months from TresibaⓇ launch. France: Months from
XultophyⓇ launch (TresibaⓇ is not launched in France).
59%
24%
novo nordiskView entire presentation